Insulin glargine, marketed under brand names like Lantus, is a long-acting insulin used to treat diabetes. Basaglar is a brand of insulin glargine that is biosimilar to Lantus.
What is the difference between insulin glargine and Basaglar?
Basaglar is a biosimilar product to insulin glargine. Biosimilars are highly similar to their reference biologic products, with no clinically meaningful differences in terms of safety, purity, and potency. Therefore, Basaglar is therapeutically equivalent to insulin glargine products like Lantus [1].
When did Basaglar become available?
Basaglar was approved by the U.S. Food and Drug Administration (FDA) in December 2015 and became available in the U.S. in December 2016 [2].
How does Basaglar compare to other insulin glargine products?
As a biosimilar, Basaglar is designed to have the same efficacy and safety profile as its reference product, insulin glargine. This means it works in the same way, is absorbed by the body at the same rate, and is expected to produce the same clinical results. Healthcare providers may consider biosimilars as interchangeable with their reference products, although official interchangeability designations are specific to each product and country [1, 2].
What are the benefits of using biosimilar insulin glargine like Basaglar?
Biosimilars, including Basaglar, can offer increased competition in the market, which may lead to lower prices for patients and healthcare systems. This can improve access to essential medications like long-acting insulin [1, 2].
What are the patent considerations for insulin glargine and its biosimilars?
The patent landscape for branded insulin glargine products like Lantus has been complex, with numerous patents covering various aspects of the drug. These patents and subsequent patent litigation have influenced the market entry of biosimilars. DrugPatentWatch.com provides detailed information on patents related to insulin glargine [3].